United States

patent 6630507 b1


On Thursday The Drug Enforcement Administration announced that it would reject petitions to reschedule marijuana as a Schedule II drug or lower. As a Schedule I drug, marijuana use is strictly prohibited outside of research. A Schedule II classification would have allowed its usage as a federally-approved prescription medical therapy.The rejection, according to a Federal Register notice, was based on an analysis by the Food and Drug Administration and recommendations from the Department of Health and Human Services.

The notice from the DEA stated the following three reasons why marijuana would not be rescheduled. Stating the potential for and history of abuse and addiction, lack of accepted medical use, and a lack of safety information. The last two reasons are part of the drug’s failure of a five-part FDA test that states that for a medicinal drug “the drug’s chemistry must be known and reproducible,” “there must be adequate safety studies,” “there must be adequate and well-controlled studies proving efficacy,” “the drug must be accepted by qualified experts,” and “the scientific evidence must be widely available.” The clinical data that could even meet the FDA’s review standards was subject to intense scrutiny. In the end, the FDA could only find 11 research articles that met its review qualifications of being randomized, double-blind, placebo-controlled clinical studies.

This decision by the DEA still keeps over 40 states and the District of Columbia that allow some form of medical marijuana usage in technical noncompliance with federal law. The decision itself also inhibits legitimate clinical research that could remedy the FDA’s lack of data. While the DEA has approved a recent study of medical marijuana in treating veterans with post-traumatic stress disorders and in 2015 relaxed its requirements for medical testing on cannabidiol marijuana extracts, the process for determining medical efficacy is complicated and difficult.

However, what we found is very contradicting as the United States of America has a U.S. Patent on Cannabinoids stating that it is an antioxidant and a neuroprotectant which was filed on April 21, 1999, and that it is useful for treating many ailments such as Alzheimer’s disease, Parkinson’s disease, and HIV dementia.

Read below to read more on the US Patent and share this article with your friends. Remember let’s think higher and knowledge is power.

United States Patent 6630507

The United States Patent Office issued patent #6630507 to the U.S.Health and Human Services filed on 2/2/2001. The patent lists the use of certain cannabinoids found within the cannabis sativa plant as useful in certain neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and HIV dementia.

Since cannabis sativa (marijuana) contains compounds recognized and endorsed by an agency of the United States government- Why is it that marijuana remains on the Federal Schedule One list of drugs? The issuance of patent #6630507 is a direct contradiction of the government’s own definition for classification of a Schedule 1 drug.       

United States Patent 6,630,507  Cannabinoids as Antioxidants and Neuroprotectants

“Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.”…

The DEA (Drug Enforcement Administration) classifies marijuana as a dangerous drug with no medical value. That classification contradicts mounds of evidence showing marijuana to be a very safe and effective medicine. Marijuana is more effective, much less expensive, and much safer than many drugs currently used in its place. Marijuana can provide excellent relief for those who suffer from cancer, AIDS, glaucoma, multiple sclerosis, chronic pain, arthritis, rheumatism, asthma, insomnia, and depression. 

If knowledge of marijuana’s many medicinal uses, its remarkable safety, and hemp’s enormous potential as a natural resource become widely known, the DEA fears that support for Marijuana Prohibition will collapse, and thus threaten the DEA’s budget. To maintain the myth that marijuana/hemp is useless and dangerous, the DEA prohibits medicinal use of marijuana, denies researchers access to marijuana for use in clinical studies, and rejects all applications to grow industrial hemp.

In 1988–after reviewing all evidence brought forth in a lawsuit against the government’s prohibition of medical marijuana–the DEA’s own administrative law judge (Judge Francis Young) wrote:

“The evidence in this record clearly shows that marijuana has been accepted as capable of relieving the distress of great numbers of very ill people and doing so with safety under medical supervision. It would be unreasonable, arbitrary and capricious for the Drug Enforcement Administration to continue to stand between those sufferers and the benefits of this substance in light of the evidence.” Judge Francis Young of the Drug Enforcement Administration went on to say: “Marijuana, in its natural form, is one of the safest therapeutically active substances known. In strict medical terms, marijuana is safer than many foods we commonly consume.”Judge Young recommended that the DEA allow marijuana to be prescribed as medicine, but the DEA has refused. -Source: US Department of Justice, Drug Enforcement Administration, “In the Matter of Marijuana Rescheduling Petition,” [Docket #86-22], (September 6, 1988), p. 57.

To stay updated on the latest tech, entrepreneurs and innovative companies in the cannabis industry, click here

This site uses Akismet to reduce spam. Learn how your comment data is processed.